References:
1. Fernandez-Egea E, McCutcheon RA. New interventions for schizophrenia: navigating the treatment landscape. Span J Psychiatry Ment Health 2026 Mar 3: S2950–2853(26)00017-7.
2. Lybalvi® (olanzapine and samidorphan). US Prescribing Information. Alkermes, January 2026. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213378s011lbl.pdf. Accessed May 21, 2026.
3. Igalmitm (dexmedetomidine). US Prescribing Information. BioXcel Therapeutics, Inc., November 2025. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215390s002lbl.pdf. Accessed May 21, 2026.
4. Correll CU, Solmi M, Cortese S, et al. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de-risk trial programmes of novel agents. World Psychiatry 2023; 22: 48–74.
5. Cherniakov I, Wagner AM, Eshet R, et al. Safety, tolerability, and pharmacokinetics of subcutaneous extended-release injectable olanzapine in patients with schizophrenia and schizoaffective disorder. Clin Drug Investig 2026; 46: 307–320.
6. Yohn SE, Harvey PD, Brannan SK, et al. The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia. Frontiers in psychiatry. Front Psychiatry 2024; 15: 1421554.
7. Kantrowitz JT, Correll CU, Jain R, et al. New developments in the treatment of schizophrenia: an expert roundtable. Int J Neuropsychopharmacol 2023; 26: 322–330.
